+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4330871
  • Drug Pipelines
  • 100 Pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • AB Science
  • Celgene Corporation
  • CerRx
  • Onxeo S.A.
  • MORE

‘Peripheral T-Cell Lymphoma (PTCL) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peripheral T-Cell Lymphoma (PTCL) in the United States, the EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Peripheral T-Cell Lymphoma (PTCL) from 2016 to 2027; segmented by the seven major markets. The Report also covers the current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States5
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Peripheral T-Cell Lymphoma (PTCL) - Disease Understanding and Treatment Algorithm

Peripheral T-cell lymphoma (PTCL) is a group of rare and usually aggressive (fast-growing) Non-Hodgkin’s Lymphomas (NHL) that develops from mature T-cells. Peripheral T-Cell Lymphoma (PTCL) comprises about 10-15% of all NHL cases in United States [Skarbnik, A.P. et.al.]

The Peripheral T cell lymphomas was classified by WHO in 2008 and updated in 2016. According to this, the Peripheral T Cell Lymphomas can be broadly classified according to the site of origin of the malignant T cell in the body - Nodal, Extranodal, Cutaneous and Leukemic. Most of the subtypes are rare and mainly 4 subtypes of PTCL- Peripheral T-Cell Lymphoma not otherwise specified (PTCL-NOS), Anaplastic Large-Cell Lymphoma (ALCL), Nasal NK/T-Cell Lymphoma and Angioimmunoblastic T-Cell Lymphoma (AITL) accounts for about 75% of the PTCL cases.

Peripheral T-Cell Lymphoma (PTCL) is also a common and treatable cause of infertility. It causes missed or irregular menstrual periods which can lead to:

  • Infertility (inability to get pregnant)
  • Development of cysts (small fluid-filled sacs) in the ovaries

The Peripheral T-Cell Lymphoma (PTCL) market report gives a thorough understanding of the Peripheral T-Cell Lymphoma (PTCL) by including details, such as disease definition, subtypes, staging, causes, symptoms, pathophysiology, diagnosis and treatment. It also provides treatment algorithms and treatment guidelines for Peripheral T-Cell Lymphoma (PTCL) in the US, Europe, and Japan.

Peripheral T-Cell Lymphoma (PTCL) Epidemiology

The Peripheral T-Cell Lymphoma (PTCL) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major market country. The report helps to recognize the causes of the current and forecasted trends by analyzing numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Incident Population of Peripheral T-Cell Lymphoma (PTCL) associated with Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL), Stage Wise Cases of Peripheral T-Cell Lymphoma (PTCL) and Common Types of Peripheral T-Cell Lymphoma (PTCL)] scenario of Peripheral T-Cell Lymphoma (PTCL) in the 7MM covering the United States, the EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the incident population of Peripheral T-Cell Lymphoma (PTCL) in the 7MM countries is expected to change during the study period i.e. 2016-2027.

The incident cases of Peripheral T Cell Lymphoma (PTCL) represent the Non-Hodgkin’s Lymphoma patient pool who are diagnosed with PTCL. In United States with the highest number of incident Peripheral T-Cell Lymphoma (PTCL) cases accounts for about 10% of all Non-Hodgkin’s Lymphoma cases. There were a total of 7,258 incident cases in 2016. In Europe, very limited number of studies are available for Peripheral T-Cell lymphoma as the indication is very rare. Based on the secondary research and KOLs, it is found that Peripheral T-Cell lymphoma (PTCL) accounted for about 8-15% of total NHL cases in EU5.

This research estimates that the total number of incident Peripheral T-Cell Lymphoma (PTCL) cases is expected to increase in 2027.

Peripheral T-Cell Lymphoma (PTCL) Drug Chapters

This segment of the Peripheral T-Cell Lymphoma (PTCL) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each of the included drug and the latest news and press releases.

The current therapeutic landscape of Peripheral T-Cell Lymphoma (PTCL) includes the detailed chapters of upcoming therapies, such as Masitinib (AB Science), Fenretinide (CerRx) and other effective emerging therapeutic products; which are expected to lead to a significant change in the market size during the forecast period [2018-2027].

Peripheral T-Cell Lymphoma (PTCL) Market Outlook

The Peripheral T-Cell Lymphoma (PTCL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and views of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at the first sight.

According to this research, the market size of Peripheral T-Cell Lymphoma (PTCL) in the seven major markets is expected to change by 2027. Current available products like Onxeo’s Beleodaq; Celgene’s Istodax and many others are occupying the Peripheral T-Cell Lymphoma (PTCL) market. The market for Peripheral T-cell Lymphoma is expanding by the approval and launch of upcoming therapies, including the recently approved Seattle’S Adcetris (Brentuximab vedotin).

The market size of Peripheral T-Cell Lymphoma (PTCL) is expected to grow due to increasing incidence as well as awareness among people that it is a treatable condition resulting in increasing diagnosis rate. It is also projected to increase due to rise in its awareness and healthcare expenditure. Additionally, launches of upcoming therapies will also contribute to the overall growth of the market during the forecast period of 2018-2027.

According to this research, the market of Peripheral T-Cell Lymphoma in 7MM was found to be 203.9 million in 2016, and is expected to increase from 2016-2027.

Peripheral T-Cell Lymphoma (PTCL) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of emerging therapies for Peripheral T-Cell Lymphoma (PTCL), such as Masitinib (AB Science) and others would fuel the growth of the market in the forecast period [2018-2027]. Other emerging drugs in the pipeline of Peripheral T-Cell Lymphoma (PTCL) are also expected to propel the growth of the Peripheral T-Cell Lymphoma (PTCL) market in the upcoming years.

Peripheral T-Cell Lymphoma (PTCL) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Peripheral T-Cell Lymphoma (PTCL) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Highly Analyzed Market
  • Key Cross Competition
  • Treatment Modalities
  • Drugs Uptake

Peripheral T-Cell Lymphoma (PTCL) Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This report will help to develop Business Strategies by understanding the trends shaping and driving Peripheral T-Cell Lymphoma (PTCL) market
  • Organize sales and marketing efforts by identifying the best opportunities for Peripheral T-Cell Lymphoma (PTCL) market
  • To understand the future market competition in the Peripheral T-Cell Lymphoma (PTCL) market

Note: We understand the needs of the rapidly changing market and the publisher is helping the client by providing the most up to date Report.

READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AB Science
  • Celgene Corporation
  • CerRx
  • Onxeo S.A.
  • MORE

1. Report Introduction

2. Peripheral T-Cell Lymphoma (PTCL) Market Overview at a Glance
2.1. 7 Major Market Size of Peripheral T-Cell Lymphoma (PTCL) in 2017
2.2. 7 Major Market Size of Peripheral T-Cell Lymphoma (PTCL) in 2027

3. Disease Background and Overview: Peripheral T-Cell Lymphoma (PTCL)
3.1. Introduction
3.2. Subtypes
3.3. Staging
3.4. Causes
3.5. Symptoms
3.6. Pathophysiology
3.7. Diagnosis
3.8. Treatment

4. Epidemiology and Patient Population
4.1. Key Findings5. 7MM
5.1. 7MM Incident cases of Peripheral T-Cell Lymphoma (PTCL) (2016-2027)
5.2. 7MM Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) (2016-2027)

6. Peripheral T-Cell Lymphoma (PTCL): Country- Wise Epidemiology
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in the United States (2016-2027)
6.1.3. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the United States (2016-2027)
6.1.4. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the United States (2016-2027)
6.1.5. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in the United States (2016-2027)
6.2. EU-5
6.2.1. Assumptions and Rationale
6.2.2. Germany
6.2.2.1. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in Germany (2016-2027)
6.2.2.2. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the Germany (2016-2027)
6.2.2.3. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the Germany (2016-2027)
6.2.2.4. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in Germany (2016-2027)
6.2.3. France
6.2.3.1. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in France (2016-2027)
6.2.3.2. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the France (2016-2027)
6.2.3.3. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the France (2016-2027)
6.2.3.4. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in France (2016-2027)
6.2.4. Italy
6.2.4.1. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in Italy (2016-2027)
6.2.4.2. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the Italy (2016-2027)
6.2.4.3. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the Italy (2016-2027)
6.2.4.4. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in Italy (2016-2027)
6.2.5. Spain
6.2.5.1. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in Spain (2016-2027)
6.2.5.2. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the Spain (2016-2027)
6.2.5.3. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the Spain (2016-2027)
6.2.5.4. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in Spain (2016-2027)
6.2.6. United Kingdom
6.2.6.1. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in United Kingdom (2016-2027)
6.2.6.2. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the United Kingdom (2016-2027)
6.2.6.3. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the United Kingdom (2016-2027)
6.2.6.4. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in United Kingdom (2016-2027)
6.2.7. Japan
6.2.7.1. Assumptions and Rationale
6.2.7.2. Incident cases of Peripheral T-Cell Lymphoma (PTCL) in Japan (2016-2027)
6.2.7.3. Stage Wise Cases Peripheral T-Cell Lymphoma (PTCL) in the Japan (2016-2027)
6.2.7.4. Common Types of Peripheral T-Cell Lymphoma (PTCL) in the Japan (2016-2027)
6.2.7.5. Diagnosed and Treatable Cases of Peripheral T-Cell Lymphoma (PTCL) in Japan (2016-2027)

7. Current Treatment & Medical Practices
7.1. Treatment Goals
7.2. Treatment Algorithm
7.3. Treatment Guidelines

8. Unmet Needs

9. Marketed Drugs
9.1. Beleodaq (Belinostat): Onxeo S.A.
9.1.1. Drug Description
9.1.2. Regulatory Milestones
9.1.3. Advantages & Disadvantages
9.1.4. Clinical Development
9.1.5. Safety and Efficacy
9.1.6. Product Profile
9.2. Istodax (Romidepsin): Celgene Corporation
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Advantages & Disadvantages
9.2.4. Clinical Development
9.2.5. Safety and Efficacy
9.2.6. Product Profile
List to be continued in report

10. Emerging Therapies
10.1. Key Cross Competition
10.2. Masitinib: AB Science
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.3.1. Clinical Trials Information
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Fenretinide: CerRx
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.3.1. Clinical Trials Information
10.3.4. Safety and Efficacy
10.3.5. Product Profile
List to be continued in report

11. Peripheral T-Cell Lymphoma (PTCL): Market Size
11.1. Key Findings
11.2. Total 7MM Peripheral T-Cell Lymphoma (PTCL) Market Analysis
11.2.1. Overview of Total Peripheral T-Cell Lymphoma (PTCL) Market, USD Million
11.2.1.1. Market size of Peripheral T-Cell Lymphoma (PTCL) by 7MM, USD Million (2016-2027)

12. 7MM Peripheral T-Cell Lymphoma (PTCL): Country-Wise Market Analysis
12.1. United States
12.1.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in the US, USD Million
12.1.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in the US, USD Million
12.2. Germany
12.2.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in Germany, USD Million
12.2.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in Germany, USD Million
12.3. France
12.3.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in France, USD Million
12.3.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in France, USD Million
12.4. United Kingdom
12.4.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in the UK, USD Million
12.4.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in the UK, USD Million
12.5. Spain
12.5.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in Spain, USD Million
12.5.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in Spain, USD Million
12.6. Italy
12.6.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in Italy, USD Million
12.6.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in Italy, USD Million
12.7. Japan
12.7.1. Total Market Size of Peripheral T-Cell Lymphoma (PTCL) in Japan, USD Million
12.7.2. Market Size of Peripheral T-Cell Lymphoma (PTCL) by Therapies in Japan, USD Million

13. Report Methodology
13.1. Sources Used

14. Capabilities

15. Disclaimer

16. About the Publisher

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AB Science
  • Celgene Corporation
  • CerRx
  • Onxeo S.A.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4330871
Adroll
adroll